The AI in Business Podcast

Enhancing Clinical Workflows and Optimizing Efficiencies - with Patricio La Rosa at Bayer

Aug 5, 2025
Patricio La Rosa, Head of End-to-End Decision Science at Bayer Crop Science, dives into AI's groundbreaking influence on clinical trials. He reveals how AI tools like metagenomics and NLP enhance biomarker discovery and improve patient outcomes. Patricio discusses building trust with patients and balancing transparency in innovative practices. His insights challenge industry leaders to view clinical trials as collaborative partnerships, urging a shift toward data-driven approaches that prioritize patient engagement and efficient workflows.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Balancing AI Cost and Scalability

  • AI solutions in clinical trials must balance cost and scalability for both R&D and real-world clinical practice.
  • Cloud providers play a crucial role in securing data and managing computational costs in AI-driven drug development.
INSIGHT

AI Must Be Clinically Scalable

  • AI tools must not only detect drug effects in trials but also be feasible and affordable for routine clinical use.
  • If sensing technologies are too costly, the scalability and patient access to monitoring suffer.
INSIGHT

Regulatory Bottlenecks Limit AI Speed

  • AI accelerates biomarker discovery but regulatory processes remain a bottleneck.
  • Faster science requires regulatory adaptation to fully realize AI-driven drug development speed.
Get the Snipd Podcast app to discover more snips from this episode
Get the app